News

Published on 29 Feb 2024 on Insider Monkey via Yahoo Finance

MannKind Corporation (NASDAQ:MNKD) Q4 2023 Earnings Call Transcript


Article preview image

MannKind Corporation (NASDAQ:MNKD) Q4 2023 Earnings Call Transcript February 27, 2024

MannKind Corporation isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here).

Operator: Good afternoon and welcome to MannKind Corporation 2023 Fourth Quarter and Full Year Financial Results Earnings Call. As a reminder, this call is being recorded on February 27, 2024, and will be available for playback on the MannKind Corporation website shortly after the conclusion of the call until March 12, 2024. This call will contain forward-looking statements. Such forward-looking statements are subject to risks and uncertainty, which could cause actual results to differ materially for those stated expectations. For further information on the Company's risk factors, please see the 10-K report filed with the Securities and Exchange Commission this afternoon, the earning release, and the slides prepared for this presentation. Joining us today from MannKind are Chief Executive Officer, Michael Castagna; and Chief Financial Officer, Steven Binder. I will now turn the conference over to Mr. Castagna. Please go ahead, sir.

NASDAQ.MNKD price evolution

Want to become a better investor?

Start tracking your investments with Statfolio

Sign up for free
Related News
MannKind Corporation's (NASDAQ:MNKD) institutional investors lost 4.0% over the...

Key Insights Given the large stake in the stock by institutions, MannKind's stock price might be...

Simply Wall St. · via Yahoo Finance 3 Feb 2025

Here’s Why MannKind Corporation (NASDAQ:MNKD) Is Among the Best Diabetes Stocks...

We recently compiled a list of the 10 Best Diabetes Stocks To Buy Under $10. In this article, we ...

Insider Monkey · via Yahoo Finance 6 Jan 2025

MannKind Corporation (MNKD): Short Seller Sentiment is Bearish on This Stock

MannKind Corporation (NASDAQ:MNKD) is a U.S.-based biopharmaceutical company focused on developin...

Insider Monkey · via Yahoo Finance 21 Sep 2024

Shareholders May Not Be So Generous With MannKind Corporation's (NASDAQ:MNKD) CEO Compensation And...

Key Insights MannKind will host its Annual General Meeting on 15th of MayCEO Michael Castagna's t...

Simply Wall St. via Yahoo Finance 9 May 2024

MannKind Corporation (NASDAQ:MNKD) Q1 2024 Earnings Call Transcript

MannKind Corporation (NASDAQ:MNKD) Q1 2024 Earnings Call Transcript May 8, 2024 MannKind Corporat...

Insider Monkey via Yahoo Finance 9 May 2024

MannKind Corporation (NASDAQ:MNKD) down to US$1.2b market cap, but institutional owners may not be...

Key Insights Given the large stake in the stock by institutions, MannKind's stock price might be ...

Simply Wall St. via Yahoo Finance 2 Apr 2024

MannKind to present new inhaled insulin study data at ATTD By Investing.com

MannKind to present new inhaled insulin study data at ATTD

Investing.com 5 Mar 2024

Analysts Just Made A Meaningful Upgrade To Their MannKind Corporation (NASDAQ:MNKD) Forecasts

Celebrations may be in order for MannKind Corporation (NASDAQ:MNKD) shareholders, with the analys...

Simply Wall St. via Yahoo Finance 3 Mar 2024

MannKind Corporation (NASDAQ:MNKD) Q4 2023 Earnings Call Transcript

MannKind Corporation (NASDAQ:MNKD) Q4 2023 Earnings Call Transcript February 27, 2024 MannKind Co...

Insider Monkey via Yahoo Finance 29 Feb 2024

MannKind (MNKD) Q4 2023 Earnings Call Transcript

Image source: The Motley Fool. MannKind (NASDAQ: MNKD)Q4 2023 Earnings CallFeb 27, 2024, 5:00 p.m...

Motley Fool via Yahoo Finance 28 Feb 2024